Richter Acquires Janssen’s Evra Transdermal Contraceptive Patch Assets for $263.5M

 Richter Acquires Janssen’s Evra Transdermal Contraceptive Patch Assets for $263.5M

Richter Acquires Janssen’s Evra Transdermal Contraceptive Patch Assets for $263.5M

Shots:

  • Richter signed an asset purchase agreement with Janssen for Evra transdermal contraceptive patch assets outside the US. The total deal value is $263.5M
  • The companies also signed a transitional business license agreement and a series of other related agreements to run the business without interruption during the period required to transfer the marketing authorizations to Richter
  • The acquisition will strengthen Richter’s position in women’s healthcare and boost its existing female healthcare franchise globally. Evra (qw) is the first transdermal hormonal patch to be approved, as well as the first non-invasive form of birth control that, when used correctly, is 99% effective

Click here ­to­ read full press release/ article | Ref: Richter | Image: Richter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post